Literature DB >> 1759834

Enantioselective disposition of ofloxacin in humans.

O Okazaki1, C Kojima, H Hakusui, M Nakashima.   

Abstract

The enantioselective disposition of ofloxacin (OFLX) was studied in healthy subjects after oral administration of (+/-)-OFLX at a dose of 200 mg. S-(-)-OFLX and R-(+)-OFLX concentrations in serum and urine were measured separately by high-performance liquid chromatography, and various pharmacokinetic parameters were calculated from the data. The ratio of S-(-) to R-(+) enantiomer concentrations in serum showed a increase with time, with S/R ratios of 1.01 at 2 h and 1.31 at 24 h. The terminal elimination half-life of S-(-)-OFLX was 6.9 h, which was significantly greater (P less than 0.05) than that of the R-(+) enantiomer (6.3 h). S-(-)-OFLX also revealed a significantly greater area under the concentration-time curve in serum, mean residence time, and total body clearance than the R-(+) enantiomer did. The renal clearance of S-(-)-OFLX (7.14 liters/h/1.73 m2) was significantly lower than that of the R-(+) enantiomer (7.53 liters/h/1.73 m2). Although the difference in the pharmacokinetic parameters of the enantiomers was small, their disposition in humans was found to be stereoselective. The difference between the enantiomers may be explained by the difference in their renal excretion.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1759834      PMCID: PMC245334          DOI: 10.1128/AAC.35.10.2106

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  23 in total

1.  Inhibitory effects of quinolones on DNA gyrase of Escherichia coli and topoisomerase II of fetal calf thymus.

Authors:  K Hoshino; K Sato; T Une; Y Osada
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

2.  Stereoselective metabolic disposition of enantiomers of ofloxacin in rats.

Authors:  O Okazaki; T Kurata; H Tachizawa
Journal:  Xenobiotica       Date:  1989-04       Impact factor: 1.908

3.  In vitro antibacterial activity of DR-3355, the S-(-)-isomer of ofloxacin.

Authors:  T Fujimoto; S Mitsuhashi
Journal:  Chemotherapy       Date:  1990       Impact factor: 2.544

4.  Transport characteristics of ceftibuten (7432-S), a new oral cephem, in rat intestinal brush-border membrane vesicles: proton-coupled and stereoselective transport of ceftibuten.

Authors:  T Yoshikawa; N Muranushi; M Yoshida; T Oguma; K Hirano; H Yamada
Journal:  Pharm Res       Date:  1989-04       Impact factor: 4.200

5.  The pharmacokinetics of ofloxacin, desmethyl ofloxacin and ofloxacin N-oxide in haemodialysis patients with end-stage renal failure.

Authors:  L O White; A P MacGowan; I G Mackay; D S Reeves
Journal:  J Antimicrob Chemother       Date:  1988-09       Impact factor: 5.790

6.  Stereoselective binding of propranolol enantiomers to human alpha 1-acid glycoprotein and human plasma.

Authors:  F Albani; R Riva; M Contin; A Baruzzi
Journal:  Br J Clin Pharmacol       Date:  1984-08       Impact factor: 4.335

7.  Synthesis and antibacterial activities of optically active ofloxacin.

Authors:  I Hayakawa; S Atarashi; S Yokohama; M Imamura; K Sakano; M Furukawa
Journal:  Antimicrob Agents Chemother       Date:  1986-01       Impact factor: 5.191

8.  The mechanism of binding of dihydropyridine calcium channel blockers to rat brain membranes.

Authors:  G A Weiland; R E Oswald
Journal:  J Biol Chem       Date:  1985-07-15       Impact factor: 5.157

9.  The pharmacokinetics of the enantiomers of mexiletine in humans.

Authors:  L Igwemezie; C R Kerr; K M McErlane
Journal:  Xenobiotica       Date:  1989-06       Impact factor: 1.908

10.  Stereospecific absorption and degradation of cephalexin.

Authors:  I Tamai; H Y Ling; S M Timbul; J Nishikido; A Tsuji
Journal:  J Pharm Pharmacol       Date:  1988-05       Impact factor: 3.765

View more
  16 in total

1.  Safety profile of enantiomers vs. racemic mixtures: it's the same?

Authors:  Céline Caillet; Laurence Chauvelot-Moachon; Jean-Louis Montastruc; Haleh Bagheri
Journal:  Br J Clin Pharmacol       Date:  2012-11       Impact factor: 4.335

2.  Effects of antacids, ferrous sulfate, and ranitidine on absorption of DR-3355 in humans.

Authors:  K Shiba; O Sakai; J Shimada; O Okazaki; H Aoki; H Hakusui
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

Review 3.  Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials.

Authors:  A Aminimanizani; P Beringer; R Jelliffe
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

4.  Local absorption kinetics of levofloxacin from intestinal tract into portal vein in conscious rat using portal-venous concentration difference.

Authors:  Y Fujieda; K Yamaoka; T Ito; T Nakagawa
Journal:  Pharm Res       Date:  1996-08       Impact factor: 4.200

5.  Absence of age and gender effects on the pharmacokinetics of a single 500-milligram oral dose of levofloxacin in healthy subjects.

Authors:  S C Chien; A T Chow; J Natarajan; R R Williams; F A Wong; M C Rogge; R K Nayak
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

6.  Intestinal elimination of ofloxacin enantiomers in the rat: evidence of a carrier-mediated process.

Authors:  L Rabbaa; S Dautrey; N Colas-Linhart; C Carbon; R Farinotti
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

7.  Pharmacodynamic modeling of the in vivo interaction between cefotaxime and ofloxacin by using serum ultrafiltrate inhibitory titers.

Authors:  D E Nix; J H Wilton; J Hyatt; J Thomas; L C Strenkoski-Nix; A Forrest; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

Review 8.  Levofloxacin: a review of its use in the treatment of bacterial infections in the United States.

Authors:  Katherine F Croom; Karen L Goa
Journal:  Drugs       Date:  2003       Impact factor: 9.546

9.  Levofloxacin disk potency and tentative interpretive criteria for susceptibility tests.

Authors:  M A Pfaller; A L Barry; P C Fuchs
Journal:  J Clin Microbiol       Date:  1993-07       Impact factor: 5.948

10.  Effects of traditional Chinese medicines on pharmacokinetics of levofloxacin.

Authors:  T Hasegawa; K Yamaki; I Muraoka; M Nadai; K Takagi; T Nabeshima
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.